Survival Time to COVID-19 Severity and Its Predictors in South Gondar Zone, North-West Ethiopia: A Prospective Cohort Study.
COVID-19
Ethiopia
South Gondar zone
predictors
time to severity
Journal
Journal of multidisciplinary healthcare
ISSN: 1178-2390
Titre abrégé: J Multidiscip Healthc
Pays: New Zealand
ID NLM: 101512691
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
02
2022
accepted:
19
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Coronavirus disease is still a global public health emergency. Due to an inadequate healthcare system in low-income nations like Ethiopia, the pandemic has had a devastating impact. Despite this, information on the severity of COVID-19 and related difficulties in Ethiopia is sparse. Therefore, we aimed to determine the survival time to severity and predictors of COVID-19 in Northwest Ethiopia. A prospective follow-up study was conducted among 202 adult COVID-19 patients in the South Gondar zone treatment centers. Data were entered using EpiData version 3.1 and then exported to Stata 16 for analysis. Kaplan-Meier was used to estimate mean survival time, and Log rank tests were used to compare survival time between explanatory variable groups. A cox-proportional hazards regression model with a 95% confidence interval and a p-value of 0.05 was used to identify covariates associated with the outcome variable. The patients' average age was 41.2 years. With an IQR of 4-7 days, the median time to COVID-19 severity was 5 days. The overall COVID-19 severity rate was 6.35 (95% CI: 5.17-7.86) per 100 person-days observed. Senior adult age group (51-59 years) (AHR = 3.59, 95% CI: 1.05, 12.23), elderly age group (≥60 years) (AHR = 2.11, 95% CI: 1.09, 12.67), comorbidity (AHR = 3.26, 95% CI: 1.48, 7.18), high blood pressure at admission (AHR = 4.36, 95% CI: 1.99, 9.54), and high temperature at admission (AHR = 5.60, 95% CI: 2.55, 12.46) were significantly associated with COVID-19 severity time. Patients with COVID-19 had a short median severity time, and factors like older age, comorbidity, high temperature, and high blood pressure were all independent predictors of severity time. Patients with high body temperature, blood pressure, comorbidity, and advanced age should be the focus of interventions to reduce progression time and improve clinical outcomes.
Sections du résumé
Background
UNASSIGNED
Coronavirus disease is still a global public health emergency. Due to an inadequate healthcare system in low-income nations like Ethiopia, the pandemic has had a devastating impact. Despite this, information on the severity of COVID-19 and related difficulties in Ethiopia is sparse. Therefore, we aimed to determine the survival time to severity and predictors of COVID-19 in Northwest Ethiopia.
Methods
UNASSIGNED
A prospective follow-up study was conducted among 202 adult COVID-19 patients in the South Gondar zone treatment centers. Data were entered using EpiData version 3.1 and then exported to Stata 16 for analysis. Kaplan-Meier was used to estimate mean survival time, and Log rank tests were used to compare survival time between explanatory variable groups. A cox-proportional hazards regression model with a 95% confidence interval and a p-value of 0.05 was used to identify covariates associated with the outcome variable.
Results
UNASSIGNED
The patients' average age was 41.2 years. With an IQR of 4-7 days, the median time to COVID-19 severity was 5 days. The overall COVID-19 severity rate was 6.35 (95% CI: 5.17-7.86) per 100 person-days observed. Senior adult age group (51-59 years) (AHR = 3.59, 95% CI: 1.05, 12.23), elderly age group (≥60 years) (AHR = 2.11, 95% CI: 1.09, 12.67), comorbidity (AHR = 3.26, 95% CI: 1.48, 7.18), high blood pressure at admission (AHR = 4.36, 95% CI: 1.99, 9.54), and high temperature at admission (AHR = 5.60, 95% CI: 2.55, 12.46) were significantly associated with COVID-19 severity time.
Conclusion and Recommendation
UNASSIGNED
Patients with COVID-19 had a short median severity time, and factors like older age, comorbidity, high temperature, and high blood pressure were all independent predictors of severity time. Patients with high body temperature, blood pressure, comorbidity, and advanced age should be the focus of interventions to reduce progression time and improve clinical outcomes.
Identifiants
pubmed: 35634568
doi: 10.2147/JMDH.S361061
pii: 361061
pmc: PMC9139343
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1187-1201Informations de copyright
© 2022 Yemata et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests in this work.
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
BMJ Open. 2021 Feb 18;11(2):e044606
pubmed: 33602713
Int Immunopharmacol. 2020 Nov;88:106950
pubmed: 32919217
Eur J Clin Invest. 2020 Oct;50(10):e13362
pubmed: 32726868
Int J Infect Dis. 2020 May;94:44-48
pubmed: 32171952
Rev Saude Publica. 2020;54:60
pubmed: 32491116
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Confl Health. 2020 Jul 31;14:54
pubmed: 32754225
Epidemiol Infect. 2021 Aug 16;149:e256
pubmed: 34392872
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Am J Infect Control. 2021 Jan;49(1):82-89
pubmed: 32540370
Pol Arch Intern Med. 2020 Apr 30;130(4):304-309
pubmed: 32231171
Hum Antibodies. 2021;29(2):139-148
pubmed: 32804122
J Infect Public Health. 2020 May;13(5):667-673
pubmed: 32340833
EClinicalMedicine. 2020 Aug;25:100471
pubmed: 32840491
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Diabetes Care. 2020 Jul;43(7):1392-1398
pubmed: 32409502
Front Cell Infect Microbiol. 2021 Oct 25;11:674277
pubmed: 34760713
Dis Mon. 2020 Sep;66(9):101068
pubmed: 32907701
Bull World Health Organ. 2021 Jan 01;99(1):62-66
pubmed: 33658735
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Autoimmun. 2020 May;109:102434
pubmed: 32143990
Lancet. 2020 Mar 14;395(10227):841-842
pubmed: 32113508
Postgrad Med J. 2021 May;97(1147):312-320
pubmed: 32978337
J Med Internet Res. 2020 Jun 30;22(6):e19636
pubmed: 32544071
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Diabetes Res Clin Pract. 2020 Dec;170:108515
pubmed: 33096185
PLoS One. 2022 Jan 27;17(1):e0262896
pubmed: 35085338
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Int J Infect Dis. 2021 Apr;105:776-783
pubmed: 33741488